Listed

ICU Medical Inc: Form 10-Q for the period ended Sep 30, 2020

Filed with the SEC on Nov 6, 2020 and accepted by EDGAR at Nov 6, 2020, 15:27 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2020-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2020-07-01 to 2020-09-30$318.6mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2020-01-01 to 2020-09-30$950.6mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2020-07-01 to 2020-09-30$204.6mus-gaap:CostOfRevenue
Cost of revenue9 months2020-01-01 to 2020-09-30$608.9mus-gaap:CostOfRevenue
Gross profit3 months2020-07-01 to 2020-09-30$113.9mus-gaap:GrossProfit
Gross profit9 months2020-01-01 to 2020-09-30$341.6mus-gaap:GrossProfit
Research and development3 months2020-07-01 to 2020-09-30$10.1mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2020-01-01 to 2020-09-30$31.2mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2020-07-01 to 2020-09-30$70.9mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2020-01-01 to 2020-09-30$210.4mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2020-07-01 to 2020-09-30$25.5mus-gaap:OperatingIncomeLoss
Operating income9 months2020-01-01 to 2020-09-30$71.1mus-gaap:OperatingIncomeLoss
Interest expense3 months2020-07-01 to 2020-09-30$616.0kus-gaap:InterestExpense
Interest expense9 months2020-01-01 to 2020-09-30$1.6mus-gaap:InterestExpense
Income tax3 months2020-07-01 to 2020-09-30$1.2mus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2020-01-01 to 2020-09-30$6.7mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2020-07-01 to 2020-09-30$25.0mus-gaap:NetIncomeLoss
Net income9 months2020-01-01 to 2020-09-30$60.7mus-gaap:ProfitLoss
Diluted EPS3 months2020-07-01 to 2020-09-30$1.16us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2020-01-01 to 2020-09-30$2.82us-gaap:EarningsPerShareDiluted
Basic EPS3 months2020-07-01 to 2020-09-30$1.19us-gaap:EarningsPerShareBasic
Basic EPS9 months2020-01-01 to 2020-09-30$2.91us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2020-07-01 to 2020-09-3021,556,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2020-01-01 to 2020-09-3021,561,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2020-01-01 to 2020-09-30$144.2mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2020-01-01 to 2020-09-30$62.4mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2020-09-30$351.0mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2020-09-30$900.1mus-gaap:AssetsCurrent
Total assetsAt period end2020-09-30$1.73bnus-gaap:Assets
Current liabilitiesAt period end2020-09-30$185.4mus-gaap:LiabilitiesCurrent
Shareholders' equityAt period end2020-09-30$1.45bnus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0000883984-20-000038. Last ingested by Listed: Nov 14, 2026, 20:54 ET. Listed shows no prices and gives no investment advice.